Christopher Labos: Ozempic's oral counterpart hasn't caught on yet

[ad_1]

Last week’s publication on clinical practice guidelines for managing childhood obesity reignited the ongoing debate on the use of Semaglutide (aka Ozempic and Wegovy). Although there is no doubt about the benefits of these drugs at present, two main adhesion points limit their wider appeal: They are expensive and require weekly injections. What many people don’t realize is that there is already a verbal form. Just not that effective. Read more

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *